¶ Ridgeback Biotherapeutics
.png)
Ridgeback Biotherapeutics is an American biotechnology company based in Miami, Florida.[1]
¶ COVID-19
Ridgeback collaborated with Merck to develop molnupiravir, an oral mutagenic anti-viral compound, to treat COVID-19. In October 2021, the two companies reported that data from their Phase 3 clinical trial showed molnupiravir “cuts the risk of hospitalization and death from COVID-19 by 50% in people who have mild to moderate forms of the disease.”[1:1][2]
In January 2022, Ridgeback and Merck announced they would supply UNICEF with 3 million doses of molnupiravir through the Access to COVID-19 Tools Accelerator (ACT-Accelerator) Therapeutics Partnership.[3]
¶ Organization
Ridgeback is a member of the Medical CBRN Defense Consortium.[4]
¶ External links
Moody, M., Ryan, P., Dannenbaum, P., Kruper, R., & Carvalho, C. (2021, October 1). Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study. Merck. Retrieved December 5, 2021, from http://archive.today/2021.11.04-114328/https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/ ↩︎ ↩︎
Halford, B., Howes, L., & Satyanarayana, M. (2021, October 1). Molnupiravir reduces risk of hospitalization and death in patients with mild to moderate COVID-19. Chemical & Engineering News; American Chemical Society. http://archive.today/2022.01.18-161431/https://cen.acs.org/pharmaceuticals/drug-development/Molnupiravir-reduces-risk-hospitalization-death/99/web/2021/10 ↩︎
Linnane, C. (2022, January 18). Merck and Ridgeback Biotherapeutics to supply 3 million doses of COVID antiviral to Unicef in 2022. MarketWatch. http://archive.today/2022.01.18-162625/https://www.marketwatch.com/story/merck-and-ridgeback-biotherapeutics-to-supply-3-million-doses-of-covid-antiviral-to-unicef-in-2022-2022-01-18 ↩︎
Current Members. MCDC. Retrieved January 3, 2023, from http://archive.today/2023.01.03-195328/https://www.medcbrn.org/current-members/ ↩︎